TY - JOUR
T1 - Methicillin-resistant staphylococcus aureus pneumonia what is the optimal duration of treatment?
AU - Zainah, Hadeel
AU - Nakhleh, Rasha
AU - Hassan, Syed
AU - Arshad, Samia
AU - Zervos, Marcus
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2013/7
Y1 - 2013/7
N2 - Background: Methicillin-resistant Staphylococcus aureus (MRSA) pneumonia is associated with high morbidity and mortality. There is no consensus about the length of therapy. Current Infectious Diseases Society of America consensus guidelines recommend 7 to 21 days for duration. Methods: In a retrospective study conducted in a 900-bed teaching hospital in urban Detroit over a 26-month period, we evaluated the charts of 706 patients with positive MRSA respiratory cultures.We studied 115 patients with MRSA pneumonia. Results: The mean ± SD age for the patients was 64.36 ± 14.44 years; 67 patients (58.77 %) were women, 44 patients (38.26%) had multilobar pneumonia. Patients were treated with either vancomycin or linezolid or treatment was switched between those 2 agents. The mean ± SD treatment duration was 13.1 ± 7.1 days. The overall 28-day mortality rate was 28.73% (n = 32). Among the 83 patients who survived to 28 days, 9 patients (10.8%) received treatment for less than 8 days, 33 patients (39.8%) received treatment for 8 to 13 days, 26 patients (31.3%) received treatment for 14 to 20 days, and 15 patients (18.1%) received treatment for more than 20 days. Among the 32 patients who did not survive to 28 days, 11 patients (34.4%) received treatment for less than 8 days, 14 patients (43.8%) received treatment for 8 to 13 days, 6 patients (18.8%) received treatment for 14 to 20 days, and 1 patient (3.1%) received treatment for more than 20 days; P < 0.001. Conclusion: The nonsurvivors were treated for shorter durations than survivors, indicating that MRSA pneumonia requires longer treatment durations (≥14 days).
AB - Background: Methicillin-resistant Staphylococcus aureus (MRSA) pneumonia is associated with high morbidity and mortality. There is no consensus about the length of therapy. Current Infectious Diseases Society of America consensus guidelines recommend 7 to 21 days for duration. Methods: In a retrospective study conducted in a 900-bed teaching hospital in urban Detroit over a 26-month period, we evaluated the charts of 706 patients with positive MRSA respiratory cultures.We studied 115 patients with MRSA pneumonia. Results: The mean ± SD age for the patients was 64.36 ± 14.44 years; 67 patients (58.77 %) were women, 44 patients (38.26%) had multilobar pneumonia. Patients were treated with either vancomycin or linezolid or treatment was switched between those 2 agents. The mean ± SD treatment duration was 13.1 ± 7.1 days. The overall 28-day mortality rate was 28.73% (n = 32). Among the 83 patients who survived to 28 days, 9 patients (10.8%) received treatment for less than 8 days, 33 patients (39.8%) received treatment for 8 to 13 days, 26 patients (31.3%) received treatment for 14 to 20 days, and 15 patients (18.1%) received treatment for more than 20 days. Among the 32 patients who did not survive to 28 days, 11 patients (34.4%) received treatment for less than 8 days, 14 patients (43.8%) received treatment for 8 to 13 days, 6 patients (18.8%) received treatment for 14 to 20 days, and 1 patient (3.1%) received treatment for more than 20 days; P < 0.001. Conclusion: The nonsurvivors were treated for shorter durations than survivors, indicating that MRSA pneumonia requires longer treatment durations (≥14 days).
KW - Duration
KW - Mrsa
KW - Pneumonia
UR - http://www.scopus.com/inward/record.url?scp=84888341641&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888341641&partnerID=8YFLogxK
U2 - 10.1097/IPC.0b013e318282630e
DO - 10.1097/IPC.0b013e318282630e
M3 - Article
AN - SCOPUS:84888341641
SN - 1056-9103
VL - 21
SP - 235
EP - 239
JO - Infectious Diseases in Clinical Practice
JF - Infectious Diseases in Clinical Practice
IS - 4
ER -